No Data
Huaxia Eye (301267.SZ): Currently does not involve AI glasses related products
Grandall 29th November | Huaxia Ophthalmology (301267.SZ) stated on the investor interaction platform that the company's main business is ophthalmology medical services, and it has not yet been involved in AI glasses related products. The company continues to closely monitor the development of new technologies and products in the ophthalmology industry, actively seeking investment opportunities that align with the company's development global strategy and planning.
Huaxia Eye Hospital GroupLtd's (SZSE:301267) Soft Earnings Don't Show The Whole Picture
Huaxia Ophthalmology: Report for the third quarter of 2024
Huaxia Ophthalmology (301267.SZ): The net income for the first three quarters is 0.421 billion yuan, a year-on-year decrease of 24.49%.
Grain Securities October 28th, Huaxia Eye (301267.SZ) announced the third quarter report of 2024, the company achieved revenue of 3.182 billion yuan in the first three quarters, a year-on-year increase of 2.55%; net income attributable to shareholders of the listed company was 0.421 billion yuan, a year-on-year decrease of 24.49%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.417 billion yuan, a year-on-year decrease of 27.23%; basic earnings per share was 0.50 yuan.
Is Huaxia Eye Hospital GroupLtd (SZSE:301267) A Risky Investment?
A Piece Of The Puzzle Missing From Huaxia Eye Hospital Group Co.,Ltd.'s (SZSE:301267) Share Price
Returns On Capital At Huaxia Eye Hospital GroupLtd (SZSE:301267) Have Hit The BrakesNo Data
No Data
